Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1993
Source ID: NCT00349427
Associated Drug: Rosiglitazone 4 Mg
Title: A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2
Interventions: DRUG: Rosiglitazone 4 mg
Outcome Measures: Primary: glycemic control at treatment 24-week measured by HbA1c (Glycosylated hemoglobin), 24 weeks | Secondary: glycemic control at treatment 24-week measured by fasting plasma glucose and daily insulin dose, proportion of subjects who reduce total daily insulin dose after treatment of 8, 16, and 24 weeks, 8, 16, and 24 weeks
Sponsor/Collaborators: Sponsor: GlaxoSmithKline
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 256
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2005-10
Completion Date:
Results First Posted:
Last Update Posted: 2012-06-04
Locations: GSK Investigational Site, Nanjing, Jiangsu, 210008, China|GSK Investigational Site, Xian, Shanxi, 710032, China|GSK Investigational Site, Beijing, 100029, China|GSK Investigational Site, Beijing, 100034, China|GSK Investigational Site, Beijing, 100730, China|GSK Investigational Site, Beijing, 100853, China|GSK Investigational Site, Shanghai, 200001, China|GSK Investigational Site, Shanghai, 200032, China|GSK Investigational Site, Shanghai, 200233, China|GSK Investigational Site, Tianjin, 300052, China
URL: https://clinicaltrials.gov/show/NCT00349427

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D116 Rosiglitazone small molecule DB00412 Details